广州高新合成生物产业投资基金注册成立

Core Insights - Guangzhou High-Tech Synthetic Biology Industry Investment Fund Partnership has been established with a capital contribution of 40 million yuan, focusing on private equity investment, investment management, and asset management activities [1][2]. Company Information - The partnership is a limited partnership and is registered in Huangpu District, Guangzhou, with a business scope that includes private equity fund activities, which require registration with the Asset Management Association of China before commencing operations [2]. - The partnership is set to operate from October 23, 2025, to September 30, 2037 [2]. Shareholder Structure - The partnership is jointly held by several entities, including: - Guangzhou Guoju Venture Capital Co., Ltd. (57.50% stake, 23 million yuan contribution) - Guangdong South China New Drug Creation Co., Ltd. (12.50% stake, 5 million yuan contribution) - State Microbiology Research Institute Group Co., Ltd. (12.50% stake, 5 million yuan contribution) - South China New Drug Creation Center (12.50% stake, 5 million yuan contribution) - Liu Qiangwei (2.50% stake, 1 million yuan contribution) [2].